In December 2013, OncoMed and Celgene Corporation announced a broad strategic collaboration to jointly develop and commercialize up to six anti-cancer stem cell product candidates from OncoMed's biologics pipeline. In exchange for significant financial commitments, Celgene gains an exclusive option to demcizumab (anti-DLL4, OMP-21M18), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), anti-RSPO3 (OMP-131R10), anti-TIGIT (OMP-313M32) and up to two additional biologics programs targeting either the RSPO-LGR CSC pathway or an additional undisclosed CSC pathway. OncoMed retains worldwide co-development rights and U.S. co-commercialization rights for five of the six biologics under the agreement. In addition, Celgene has the option to pursue a small molecule discovery program against the undisclosed pathway. OncoMed received a $177.25 million upfront payment, including a $22.25 million equity investment. The collaboration also includes option exercise payments and payments for achievement of development, regulatory and commercial milestones, paid on a per-program basis. OncoMed will also receive royalty payments based on future product sales.
In June 2010, OncoMed entered into a strategic alliance with Bayer HealthCare to discover, develop and commercialize novel anti-cancer stem cell therapeutics. Under the agreement, Bayer and OncoMed will develop up to five agents targeting the Wnt signaling pathway through Phase I. Two products, vantictumab (anti-Fzd, OMP-18R5) and ipafricept (Fzd8-Fc, OMP-54F28) emerged from these discovery efforts and advanced into clinical studies. Upfront and milestone payments of over $90 million from Bayer have been received to support the discovery and development of these therapeutics through multiple Phase 1b clinical trials. In April 2017, Bayer notified us that they would not be seeking to exercise their option to in-license vantictumab and ipafricept. OncoMed retains worldwide development and commercialization rights to vantictumab, ipafricept and all other Wnt pathway biologics under the collaboration. The small molecule program under the companies’ collaboration continues without change. For any small molecule candidates (for which Bayer will lead discovery and development efforts), OncoMed's payments could total up to $112 million per program in addition to single digit percentage royalties on net product sales.
In April 2011, OncoMed and Bayer expanded their collaboration, executing a clinical manufacturing agreement, whereby Bayer would manufacture a Wnt pathway biologic at their Berkeley, California facility.
In December 2007, OncoMed and GSK entered into a strategic alliance to develop cancer stem cell antibody therapeutics targeting the Notch signaling pathway. In July 2011, OncoMed amended the terms of its research and development agreement with GSK, and the collaboration is now focused entirely on the development of tarextumab (anti-Notch2/3, OMP-59R5). Under this collaboration, OncoMed is eligible to receive aggregate payments of up to $344.5 million, in addition to percentage royalties in the low double digits to high teens on net product sales.